首页> Kidney international reports> Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan.

Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan.

导出 LinkOut

翻译打印收藏纠错

第一作者： Kiyotaka,Uchiyama

第一单位： Department of Nephrology, International University of Health and Welfare Narita Hospital, Chiba, Japan.;Department of Nephrology, Japanese Red Cross Medical Center, Tokyo, Japan.

作者： Kiyotaka,Uchiyama ^[1] ; Daisuke,Kamano ^[2] ; Tomoki,Nagasaka ^[3] ; Eriko Yoshida,Hama ^[3] ; Ryoichi,Shirai ^[2] ; Rena,Sumura ^[2] ; Ei,Kusahana ^[3] ; Akane,Yanai ^[4] ; Takashin,Nakayama ^[3] ; Takahide,Kimura ^[5] ; Rina,Takahashi ^[3] ; Takahiro,Kasai ^[5] ; Takaya,Tajima ^[3] ; Koji,Hosoya ^[6] ; Tatsuhiko,Azegami ^[3] ; Shintaro,Yamaguchi ^[3] ; Jun,Yoshino ^[7] ; Jun,Ito ^[8] ; Matsuhiko,Hayashi ^[9] ; Takeshi,Kanda ^[7] ; Yoshitaka,Ishibashi ^[2] ; Naoki,Washida ^[8] ; Hiroshi,Itoh ^[3] ; Kaori,Hayashi ^[3]

作者单位： Department of Nephrology, International University of Health and Welfare Narita Hospital, Chiba, Japan.;Department of Nephrology, Japanese Red Cross Medical Center, Tokyo, Japan. ^[1] Department of Nephrology, Japanese Red Cross Medical Center, Tokyo, Japan. ^[2] Division of Endocrinology, Metabolism and Nephrology Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. ^[3] Department of Nephrology, Tokyo Shinagawa Hospital, Tokyo, Japan. ^[4] Department of Nephrology, International University of Health and Welfare Atami Hospital, Shizuoka, Japan. ^[5] Department of Nephrology, International University of Health and Welfare Hospital, Tochigi, Japan. ^[6] Division of Nephrology, Shimane University Hospital, Shimane, Japan. ^[7] Department of Nephrology, International University of Health and Welfare Narita Hospital, Chiba, Japan. ^[8] Department of Nephrology, Kawakita General Hospital, Tokyo, Japan. ^[9]

关键词 autosomal dominant polycystic kidney disease dapagliflozin estimated glomerular filtration rate sodium–glucose cotransporter 2 inhibitor tolvaptan total kidney volume

DOI 10.1016/j.ekir.2025.01.023

PMID 40303212

发布时间 2025-07-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Kidney international reports

2025年10卷4期

1063-1075页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Kidney international reports

2025年10卷4期

1063-1075页

检索历史清除

Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan.

Kidney international reports

相似文献

Kidney international reports

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan.

Kidney international reports

相似文献

Kidney international reports

相关期刊

检索历史清除